In a filing, Adaptimmune Therapeutics Plc ADR revealed its 10% Owner EcoR1 Capital, LLC unloaded Company’s shares for reported $3.82 million on Jul 28 ’25. In the deal valued at $0.11 per share,33,931,740 shares were sold. As a result of this transaction, EcoR1 Capital, LLC now holds 130,492,680 shares worth roughly $10.44 million.
Then, EcoR1 Capital, LLC sold 27,433,338 shares, generating $2,800,944 in total proceeds. Upon selling the shares at $0.10, the 10% Owner now owns 100,371,882 shares.
Before that, EcoR1 Capital, LLC sold 2,687,460 shares. Adaptimmune Therapeutics Plc ADR shares valued at $271,971 were divested by the 10% Owner at a price of $0.10 per share. As a result of the transaction, EcoR1 Capital, LLC now holds 127,805,220 shares, worth roughly $10.22 million.
H.C. Wainwright downgraded its Adaptimmune Therapeutics Plc ADR [ADAP] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Mizuho’s analysts, who decreased its forecast for the stock in late June from “an Outperform” to “a Neutral”. H.C. Wainwright began covering ADAP with “Buy” recommendation on July 30, 2024. Scotiabank started covering the stock on May 30, 2024. It rated ADAP as “a Sector outperform”.
Price Performance Review of ADAP
On Friday, Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] saw its stock fall -0.50% to $0.08. Over the last five days, the stock has lost -76.97%. Adaptimmune Therapeutics Plc ADR shares have fallen nearly -93.85% since the year began. Nevertheless, the stocks have fallen -85.17% over the past one year. While a 52-week high of $1.36 was reached on 01/06/25, a 52-week low of $0.08 was recorded on 07/31/25.
Levels Of Support And Resistance For ADAP Stock
The 24-hour chart illustrates a support level at 0.0755, which if violated will result in even more drops to 0.0712. On the upside, there is a resistance level at 0.0867. A further resistance level may holdings at 0.0936.
How much short interest is there in Adaptimmune Therapeutics Plc ADR?
A steep rise in short interest was recorded in Adaptimmune Therapeutics Plc ADR stocks on 2025-07-15, dropping by -0.68 million shares to a total of 3.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 4.56 million shares. There was a decline of -17.48%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 24, 2023 when Bryan Garnier began covering the stock and recommended ‘”a Buy”‘ rating along with a $3.60 price target.
